- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-2-2-6-mer
- Ligands
- 58 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 64 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)
NAG.59: 1 residues within 4Å:- Chain A: N.178
Ligand excluded by PLIPNAG.60: 3 residues within 4Å:- Chain A: R.198, N.202, N.496
Ligand excluded by PLIPNAG.61: 2 residues within 4Å:- Chain A: G.373, N.374
Ligand excluded by PLIPNAG.62: 1 residues within 4Å:- Chain A: N.388
Ligand excluded by PLIPNAG.64: 2 residues within 4Å:- Chain B: K.321, N.334
Ligand excluded by PLIPNAG.66: 1 residues within 4Å:- Chain C: N.178
Ligand excluded by PLIPNAG.67: 3 residues within 4Å:- Chain C: R.198, N.202, N.496
Ligand excluded by PLIPNAG.68: 2 residues within 4Å:- Chain C: G.373, N.374
Ligand excluded by PLIPNAG.69: 1 residues within 4Å:- Chain C: N.388
Ligand excluded by PLIPNAG.71: 2 residues within 4Å:- Chain D: K.321, N.334
Ligand excluded by PLIPNAG.73: 2 residues within 4Å:- Chain E: Y.28, N.61
Ligand excluded by PLIPNAG.74: 3 residues within 4Å:- Chain E: N.122, T.124, V.127
Ligand excluded by PLIPNAG.75: 2 residues within 4Å:- Chain E: E.132, N.165
Ligand excluded by PLIPNAG.76: 4 residues within 4Å:- Chain E: G.232, N.234
- Chain G: E.465, R.466
Ligand excluded by PLIPNAG.77: 4 residues within 4Å:- Chain E: N.280, E.281, N.282
- Chain G: K.558
Ligand excluded by PLIPNAG.78: 2 residues within 4Å:- Chain E: N.603, T.604
Ligand excluded by PLIPNAG.79: 1 residues within 4Å:- Chain E: N.616
Ligand excluded by PLIPNAG.80: 1 residues within 4Å:- Chain E: N.657
Ligand excluded by PLIPNAG.81: 3 residues within 4Å:- Chain E: N.709, G.1131
- Chain F: D.796
Ligand excluded by PLIPNAG.82: 2 residues within 4Å:- Chain F: Y.28, N.61
Ligand excluded by PLIPNAG.83: 3 residues within 4Å:- Chain F: N.122, T.124, V.127
Ligand excluded by PLIPNAG.84: 2 residues within 4Å:- Chain F: E.132, N.165
Ligand excluded by PLIPNAG.85: 2 residues within 4Å:- Chain F: G.232, N.234
Ligand excluded by PLIPNAG.86: 3 residues within 4Å:- Chain F: N.280, E.281, N.282
Ligand excluded by PLIPNAG.87: 2 residues within 4Å:- Chain F: N.603, T.604
Ligand excluded by PLIPNAG.88: 1 residues within 4Å:- Chain F: N.616
Ligand excluded by PLIPNAG.89: 1 residues within 4Å:- Chain F: N.657
Ligand excluded by PLIPNAG.90: 5 residues within 4Å:- Chain F: A.706, E.1072, K.1073, N.1074
- Ligands: NAG.91
Ligand excluded by PLIPNAG.91: 1 residues within 4Å:- Ligands: NAG.90
Ligand excluded by PLIPNAG.92: 2 residues within 4Å:- Chain G: Y.28, N.61
Ligand excluded by PLIPNAG.93: 3 residues within 4Å:- Chain G: N.122, T.124, V.127
Ligand excluded by PLIPNAG.94: 2 residues within 4Å:- Chain G: E.132, N.165
Ligand excluded by PLIPNAG.95: 2 residues within 4Å:- Chain F: E.465
- Chain G: N.234
Ligand excluded by PLIPNAG.96: 4 residues within 4Å:- Chain F: K.558
- Chain G: N.280, E.281, N.282
Ligand excluded by PLIPNAG.97: 2 residues within 4Å:- Chain G: N.603, T.604
Ligand excluded by PLIPNAG.98: 1 residues within 4Å:- Chain G: N.616
Ligand excluded by PLIPNAG.99: 1 residues within 4Å:- Chain G: N.657
Ligand excluded by PLIPNAG.100: 2 residues within 4Å:- Chain H: Y.28, N.61
Ligand excluded by PLIPNAG.101: 3 residues within 4Å:- Chain H: N.122, T.124, V.127
Ligand excluded by PLIPNAG.102: 2 residues within 4Å:- Chain H: E.132, N.165
Ligand excluded by PLIPNAG.103: 4 residues within 4Å:- Chain H: G.232, N.234
- Chain J: E.465, R.466
Ligand excluded by PLIPNAG.104: 4 residues within 4Å:- Chain H: N.280, E.281, N.282
- Chain J: K.558
Ligand excluded by PLIPNAG.105: 2 residues within 4Å:- Chain H: N.603, T.604
Ligand excluded by PLIPNAG.106: 1 residues within 4Å:- Chain H: N.616
Ligand excluded by PLIPNAG.107: 1 residues within 4Å:- Chain H: N.657
Ligand excluded by PLIPNAG.108: 3 residues within 4Å:- Chain H: N.709, G.1131
- Chain I: D.796
Ligand excluded by PLIPNAG.109: 2 residues within 4Å:- Chain I: Y.28, N.61
Ligand excluded by PLIPNAG.110: 3 residues within 4Å:- Chain I: N.122, T.124, V.127
Ligand excluded by PLIPNAG.111: 2 residues within 4Å:- Chain I: E.132, N.165
Ligand excluded by PLIPNAG.112: 2 residues within 4Å:- Chain I: G.232, N.234
Ligand excluded by PLIPNAG.113: 3 residues within 4Å:- Chain I: N.280, E.281, N.282
Ligand excluded by PLIPNAG.114: 2 residues within 4Å:- Chain I: N.603, T.604
Ligand excluded by PLIPNAG.115: 1 residues within 4Å:- Chain I: N.616
Ligand excluded by PLIPNAG.116: 1 residues within 4Å:- Chain I: N.657
Ligand excluded by PLIPNAG.117: 5 residues within 4Å:- Chain I: A.706, E.1072, K.1073, N.1074
- Ligands: NAG.118
Ligand excluded by PLIPNAG.118: 1 residues within 4Å:- Ligands: NAG.117
Ligand excluded by PLIPNAG.119: 2 residues within 4Å:- Chain J: Y.28, N.61
Ligand excluded by PLIPNAG.120: 3 residues within 4Å:- Chain J: N.122, T.124, V.127
Ligand excluded by PLIPNAG.121: 2 residues within 4Å:- Chain J: E.132, N.165
Ligand excluded by PLIPNAG.122: 2 residues within 4Å:- Chain I: E.465
- Chain J: N.234
Ligand excluded by PLIPNAG.123: 4 residues within 4Å:- Chain I: K.558
- Chain J: N.280, E.281, N.282
Ligand excluded by PLIPNAG.124: 2 residues within 4Å:- Chain J: N.603, T.604
Ligand excluded by PLIPNAG.125: 1 residues within 4Å:- Chain J: N.616
Ligand excluded by PLIPNAG.126: 1 residues within 4Å:- Chain J: N.657
Ligand excluded by PLIP- 2 x LEU: LEUCINE(Non-covalent)
LEU.63: 12 residues within 4Å:- Chain A: F.68, C.69, V.70, G.71, L.72, Y.149, F.297, S.298, S.300, F.303, S.451, N.455
5 PLIP interactions:5 interactions with chain A,- Hydrophobic interactions: A:F.68, A:Y.149, A:F.303
- Hydrogen bonds: A:F.68, A:F.297
LEU.70: 12 residues within 4Å:- Chain C: F.68, C.69, V.70, G.71, L.72, Y.149, F.297, S.298, S.300, F.303, S.451, N.455
5 PLIP interactions:5 interactions with chain C,- Hydrophobic interactions: C:F.68, C:Y.149, C:F.303
- Hydrogen bonds: C:F.68, C:F.297
- 2 x ZN: ZINC ION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yan, R. et al., Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2. Cell Res. (2021)
- Release Date
- 2021-03-31
- Peptides
- Sodium-dependent neutral amino acid transporter B(0)AT1: AC
Angiotensin-converting enzyme 2: BD
Spike glycoprotein: EFGHIJ - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CB
BD
DE
EF
FG
GH
HI
IJ
J - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-2-2-6-mer
- Ligands
- 58 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 64 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)
- 2 x LEU: LEUCINE(Non-covalent)
- 2 x ZN: ZINC ION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yan, R. et al., Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2. Cell Res. (2021)
- Release Date
- 2021-03-31
- Peptides
- Sodium-dependent neutral amino acid transporter B(0)AT1: AC
Angiotensin-converting enzyme 2: BD
Spike glycoprotein: EFGHIJ - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CB
BD
DE
EF
FG
GH
HI
IJ
J - Membrane
-
We predict this structure to be a membrane protein.